{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pharmacodynamics&page=5",
    "query": {
      "intervention": "Pharmacodynamics",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 3444,
    "total_pages": 345,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pharmacodynamics&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pharmacodynamics&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T09:02:06.437Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01906489",
      "title": "20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anemia",
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "AKB-6548",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Akebia Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "82 Years",
        "sex": "ALL",
        "summary": "18 Years to 82 Years"
      },
      "enrollment_count": 210,
      "start_date": "2013-07-23",
      "completion_date": "2014-09-03",
      "has_results": true,
      "last_update_posted_date": "2022-07-21",
      "last_synced_at": "2026-11-15T09:02:06.437Z",
      "location_count": 47,
      "location_summary": "Glendale, Arizona • Tucson, Arizona • Azusa, California + 44 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Azusa",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Downey",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01906489"
    },
    {
      "nct_id": "NCT05119335",
      "title": "A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "ccRCC",
        "Clear Cell Renal Cell Carcinoma",
        "Kidney Cancer",
        "Kidney Neoplasms",
        "Renal Cancer",
        "Renal Neoplasms",
        "Recurrent Renal Cell Carcinoma",
        "Metastatic Renal Cell Carcinoma",
        "Refractory Renal Cell Carcinoma",
        "Advanced Renal Cell Carcinoma",
        "Hypoxia",
        "Renal Cell Carcinoma",
        "Hypoxia Inducible Factor (HIF)",
        "HIF2α Inhibitor",
        "Hypoxia Inducible Factor 2 Alpha (HIF-2 Alpha)",
        "Hypoxia Inducible Factor 2α (HIF-2α)",
        "Clear Cell"
      ],
      "interventions": [
        {
          "name": "Oral NKT2152",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NiKang Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2021-10-26",
      "completion_date": "2025-09-30",
      "has_results": false,
      "last_update_posted_date": "2025-11-12",
      "last_synced_at": "2026-11-15T09:02:06.437Z",
      "location_count": 13,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 10 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05119335"
    },
    {
      "nct_id": "NCT02641990",
      "title": "Study of the Effect of ITCA 650 on the PK/PD of Oral Contraceptive in Healthy Female Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Adult Premenopausal Female Volunteers"
      ],
      "interventions": [
        {
          "name": "ITCA 650 20/60 mcg/day, ITCA placebo",
          "type": "DRUG"
        },
        {
          "name": "ITCA placebo, ITCA 650 20/60 mcg/day",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Intarcia Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 28,
      "start_date": "2015-12",
      "completion_date": "2016-02",
      "has_results": false,
      "last_update_posted_date": "2016-03-22",
      "last_synced_at": "2026-11-15T09:02:06.437Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Orlando, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02641990"
    },
    {
      "nct_id": "NCT02341508",
      "title": "A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Subjects"
      ],
      "interventions": [
        {
          "name": "0.5 mg/kg Lpathomab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "1.0 mg/kg Lpathomab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "3.0 mg/kg Lpathomab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "10 mg/kg Lpathomab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "20 mg/kg Lpathomab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline solution for intravenous infusion",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Lpath, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2015-09",
      "completion_date": "2016-03",
      "has_results": false,
      "last_update_posted_date": "2016-05-06",
      "last_synced_at": "2026-11-15T09:02:06.437Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02341508"
    },
    {
      "nct_id": "NCT00963768",
      "title": "A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "JNJ 28431754",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "25 Years to 65 Years"
      },
      "enrollment_count": 116,
      "start_date": "2007-06",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2014-04-23",
      "last_synced_at": "2026-11-15T09:02:06.437Z",
      "location_count": 1,
      "location_summary": "Chula Vista, California",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00963768"
    },
    {
      "nct_id": "NCT00343954",
      "title": "PK and PD Responses to Oral L-Citrulline in Patients With Sickle Cell Disease",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "L-citrulline tablets, 1000 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Angiogenix",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 12,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2006-06-23",
      "last_synced_at": "2026-11-15T09:02:06.437Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00343954"
    },
    {
      "nct_id": "NCT01537497",
      "title": "A Study To Evaluate The Effects Of PF-05175157 In Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "PF-05175157",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 31,
      "start_date": "2012-03",
      "completion_date": "2012-05",
      "has_results": false,
      "last_update_posted_date": "2012-07-10",
      "last_synced_at": "2026-11-15T09:02:06.437Z",
      "location_count": 1,
      "location_summary": "South Miami, Florida",
      "locations": [
        {
          "city": "South Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01537497"
    },
    {
      "nct_id": "NCT00547560",
      "title": "Study Evaluating Multiple Doses Of GSI-953 Within The Elderly Population",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "GSI-953",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2007-08",
      "completion_date": "2009-10",
      "has_results": false,
      "last_update_posted_date": "2011-04-04",
      "last_synced_at": "2026-11-15T09:02:06.437Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00547560"
    },
    {
      "nct_id": "NCT01000961",
      "title": "Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cystinosis"
      ],
      "interventions": [
        {
          "name": "Cystagon® (Cysteamine Bitartrate)",
          "type": "DRUG"
        },
        {
          "name": "Cysteamine Bitartrate Delayed-release Capsules (RP103)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2010-06",
      "completion_date": "2011-08",
      "has_results": true,
      "last_update_posted_date": "2024-12-19",
      "last_synced_at": "2026-11-15T09:02:06.437Z",
      "location_count": 3,
      "location_summary": "Stanford, California • Atlanta, Georgia • Chicago, Illinois",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01000961"
    },
    {
      "nct_id": "NCT00474760",
      "title": "Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sarcoma, Ewing's"
      ],
      "interventions": [
        {
          "name": "CP-751,871",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "9 Years and older"
      },
      "enrollment_count": 65,
      "start_date": "2005-08",
      "completion_date": "2012-10",
      "has_results": true,
      "last_update_posted_date": "2013-12-17",
      "last_synced_at": "2026-11-15T09:02:06.437Z",
      "location_count": 2,
      "location_summary": "Ann Arbor, Michigan • Rochester, Minnesota",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00474760"
    }
  ]
}